Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.50 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1130922 | 0.89 | ZDHHC2 (0.59) | EPHX2HPGDZDHHC2 | |
| SCHEMBL1993452 | 0.89 | ZDHHC2 (0.59) | EPHX2HPGDZDHHC2 | |
| SCHEMBL8385262 | 0.89 | ZDHHC2 (0.59) | EPHX2HPGDZDHHC2 | |
| SCHEMBL8387295 | 0.89 | ZDHHC2 (0.59) | EPHX2HPGDZDHHC2 | |
| SCHEMBL19617998 | 0.86 | HPGD (0.56) | EPHX2HPGDHDAC1HDAC2 | |
| SCHEMBL10030729 | 0.86 | HPGD (0.56) | EPHX2HPGDHDAC1HDAC2 | |
| Sulfuric Acid SCHEMBL8433373 | 0.85 | ZDHHC2 (0.55) | EPHX2HPGDZDHHC2 | |
| SCHEMBL10030727 | 0.84 | MEN1 (0.57) | EPHX2HPGDSIRT2SIRT1 | |
| SCHEMBL16589850 | 0.83 | SMN1; SMN2 (0.54) | HPGDZDHHC2 | |
| SCHEMBL10030730 | 0.82 | HPGD (0.54) | EPHX2HPGDSIRT2HDAC8HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210922-A1 | 3D PRINTING SYSTEM COMPRISING SOLID BUILD INK COMPRISING COLORANT | XEROX CORPORATION | 2017-07-27 | — | — | US | disclosed |
| US-20170210922-A1 | 3D PRINTING SYSTEM COMPRISING SOLID BUILD INK COMPRISING COLORANT | XEROX CORPORATION | 2017-07-27 | — | — | US | disclosed |
| US-9676952-B2 | 3D printing system comprising solid build ink comprising colorant | XEROX CORPORATION (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676952-B2 | 3D printing system comprising solid build ink comprising colorant | XEROX CORPORATION (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160244628-A1 | 3D PRINTING SYSTEM COMPRISING SOLID BUILD INK COMPRISING COLORANT | XEROX CORPORATION | 2016-08-25 | — | — | US | disclosed |
| US-20160244628-A1 | 3D PRINTING SYSTEM COMPRISING SOLID BUILD INK COMPRISING COLORANT | XEROX CORPORATION | 2016-08-25 | — | — | US | disclosed |
| US-9012527-B2 | Curable compositions for three-dimensional printing | XEROX CORPORATION (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012527-B2 | Curable compositions for three-dimensional printing | XEROX CORPORATION (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140171537-A1 | Orange Curable Ink | XEROX CORPORATION (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171537-A1 | Orange Curable Ink | XEROX CORPORATION (US) | 2014-06-19 | — | — | US | disclosed |
| US-8084637-B2 | Amide gellant compounds with aromatic end groups | XEROX CORPORATION (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084637-B2 | Amide gellant compounds with aromatic end groups | XEROX CORPORATION (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110262643-A1 | INK COMPOSITIONS AND METHODS | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262643-A1 | INK COMPOSITIONS AND METHODS | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263890-A1 | Amide Gellant Compounds With Aromatic End Groups | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262711-A1 | CURABLE COMPOSITIONS FOR THREE-DIMENSIONAL PRINTING | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263769-A1 | Phase Change Inks Containing Amide Gellant Compounds With Aromatic End Groups | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263769-A1 | Phase Change Inks Containing Amide Gellant Compounds With Aromatic End Groups | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262711-A1 | CURABLE COMPOSITIONS FOR THREE-DIMENSIONAL PRINTING | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263890-A1 | Amide Gellant Compounds With Aromatic End Groups | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263890-A1 | Amide Gellant Compounds With Aromatic End Groups | NAT1, AGPAT2, CCNT1 | EPHX2 1171/4885ASAH1 1670/4885HPGD 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.